Document Detail


Argatroban as novel therapy for suspected thrombosis in patients with continuous flow left ventricle assist device and hemolysis.
MedLine Citation:
PMID:  24614354     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
The growing use of left ventricular assisted devices as bridge to transplant and their increased duration as destination therapy in patients successfully treated for advance heart failure unwrap a new spectrum of complications seen in long-term use of the devices. Device thrombosis remains a therapeutic dilemma and limited data is available for use of direct thrombin inhibitors as a treatment option.We performed a review of literature and present a series of four patients with suspected left ventricular assisted device associated thrombosis, manifesting as hemolysis, who were treated empirically with argotraban, a direct thrombin inhibitor with ability to interact with both free and clot-bound thrombin. In this case series we treated four patients with argatroban for suspected device thrombosis. All of them showed significant improvement of hemolysis by lactate dehydrogenase measurements and prevented device removal in three of them. Bleeding complications occurred when therapy was used closer to the operative period.Argatroban can be a viable option to treat patients with hemolysis from suspected device thrombosis in patients with HeartMate II continuous flow left ventricular assisted device. Prompt attention is needed to monitor any bleeding complications.
Authors:
Amit Badiye; Gabriel A Hernandez; Sandra Chaparro
Related Documents :
16287954 - High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocard...
21040324 - An invasive management strategy is associated with improved outcomes in high-risk acute...
11962564 - Use of emergency medical services for suspected acute cardiac ischemia among demographi...
17892984 - Effects of carvedilol early after myocardial infarction: analysis of the first 30 days ...
15670624 - Cells, scaffolds, and molecules for myocardial tissue engineering.
9583444 - Cardioprotective effect of intravenous nicorandil in patients with successful reperfusi...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-3-7
Journal Detail:
Title:  ASAIO journal (American Society for Artificial Internal Organs : 1992)     Volume:  -     ISSN:  1538-943X     ISO Abbreviation:  ASAIO J.     Publication Date:  2014 Mar 
Date Detail:
Created Date:  2014-3-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9204109     Medline TA:  ASAIO J     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  In Silico Prediction of Inhibition of Promiscuous Breast Cancer Resistance Protein (BCRP/ABCG2).
Next Document:  The Association of Pre-transplant HeartMate® II Left Ventricular Assist Device Placement and Heart ...